Revisiting amlodipine induced pedal edema: a student’s perspective

Authors

  • Swathi Nemani Student-Alumni, Kasturba Medical College-International Center (KMC-IC), Manipal, India
  • Yeshwanth Rao Professor & Course Director, Department of Pharmacology, Kasturba Medical College-International Center (KMC-IC), Manipal, India

Keywords:

Amlodipine, Pedal edema

Abstract

Amlodipine, a dihydropyridine, is used frequently used in the treatment of hypertension and angina pectoris. The drug acts by blocking the L-gated calcium channels which causes the blood vessels to relax. It's taken orally and excreted through the urine like many other drugs. Calcium channel blockers are usually well tolerated but as always exceptions always exist. Common side effects are constipation, dizziness, flushing, and pre-tibial edema. Pre-tibial edema has been a very common side effect that has lead the drug to be withdrawn in some patients therapy.

References

Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994:51:59-68.

Sica DA. Calcium Channel Blocker-Related Peripheral Edema: Can It Be Resolved? J Clin Hypertens (Greenwich) 2003;5:291-4.

DeWitt CR, Waksman JC. Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and β-Blocker Toxicity. Toxicol Rev 2004:23(4):223-38.

Pardeshi M, SV Dange SV. Comparison of Efficacy and Safety of Amlodipine and Felodipine-ER in Patients of Essential Hypertension. Bombay Hospital Journal 2004:46(2).

Messerli FH, Grossman E. Pedal Edema-Not All Dihydropyridine Calcium Antagonists Are Created Equal. AJH 2002;15:1019-20.

Juan Carlos Pelayo, Wahd Nuri. Medical/Statistical Review. P.44.

Chrysant SG, Sugimoto DH, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press Suppl 2007;1:10-7.

Downloads

Published

2017-02-01

How to Cite

Nemani, S., & Rao, Y. (2017). Revisiting amlodipine induced pedal edema: a student’s perspective. International Journal of Basic & Clinical Pharmacology, 2(5), 661–662. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/1342

Issue

Section

Letter to the Editor